Bionomics is a fully integrated, international drug discovery and development company creating new therapies that serve large unmet needs in cancer and central nervous system (CNS) disorders. Based in Adelaide, Australia with operations in San Diego, USA and a wholly owned subsidiary in Strasbourg, France, Bionomics is listed on the Australian Securities Exchange (ASX) under the code BNO, and the US OTCQX market under the code BNOEF.

ASX Announcements

  • Bionomics Receives Over $6.7m R&D Tax Incentive Refund

    16 January 2018

    Download PDF

  • Bionomics to Feature at Neuroscience Innovation Forum and Biotech Showcase in San Francisco

    05 January 2018

    Download PDF

  • Chairman's Address Bionomics Annual General Meeting 2017

    15 November 2017

    Download PDF


Latest Analyst Report